how big is Pharmaids Pharma?

As of Jun 06, Pharmaids Pharmaceuticals Ltd has a market capitalization of 201.73 Cr, with recent net sales of 19.39 Cr and a net profit of -10.77 Cr. Shareholder's funds are 72.05 Cr, and total assets amount to 84.67 Cr.

Market Cap: As of Jun 06, Pharmaids Pharmaceuticals Ltd has a market capitalization of 201.73 Cr, classifying it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Pharmaids Pharmaceuticals Ltd reported a sum of Net Sales of 19.39 Cr and a sum of Net Profit of -10.77 Cr. This data is presented on a Consolidated basis.<BR><BR>Balance Sheet Snapshot: The balance sheet data is also on a Consolidated basis for the latest annual period ending in Mar'24. Shareholder's Funds are reported at 72.05 Cr, while Total Assets amount to 84.67 Cr.

What does Pharmaids Pharma do?

Pharmaids Pharmaceuticals Ltd is a micro-cap company based in Hyderabad, specializing in specialty chemicals, skin care, hospital care, and generic products. As of March 2025, it reported net sales of 5 Cr and a net loss of 4 Cr, with a market cap of Rs 204 Cr.

Overview:<BR>Pharmaids Pharmaceuticals Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology industry, specializing in the supply of quality specialty chemicals, skin care, hospital care, and generic products.<BR><BR>History:<BR>Incorporated in March 1989 in Hyderabad, Telangana, Pharmaids Pharmaceuticals Ltd has maintained its operations in the pharmaceuticals sector. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 5 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: -4 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 204 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: N/A (Loss Making)<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.62<BR>- Return on Equity: -18.00%<BR>- Price to Book: 3.51<BR><BR>Contact Details:<BR>Address: 4-4-211/212/3 1st Floor, Inderbagh Sulthan Bazar Hyderabad Telangana : 500095 <BR>Tel: 91-40-66669809 <BR>Email: mailpharmaids@yahoo.co.in <BR>Website: http://www.pharmaids.com

Who are in the management team of Pharmaids Pharma?

As of March 2023, the management team of Pharmaids Pharma includes Venu Madhava Kaparthy, Mini Manikantan, Sadhanala Venkata Rao, P N Vijay, M Sudheer Anand, Methuku Nagesh, and Shreedhara Shetty, comprising both executive and independent directors.

As of March 2023, the management team of Pharmaids Pharma includes the following individuals:<BR><BR>1. Venu Madhava Kaparthy - Executive Director & Wholetime Director<BR>2. Mini Manikantan - Executive Director & Wholetime Director<BR>3. Sadhanala Venkata Rao - Non-Executive & Non-Independent Director<BR>4. P N Vijay - Independent Non-Executive Director<BR>5. M Sudheer Anand - Independent Non-Executive Director<BR>6. Methuku Nagesh - Independent Non-Executive Director<BR>7. Shreedhara Shetty - Additional Director<BR><BR>This team comprises a mix of executive and non-executive directors, contributing to the governance and strategic direction of the company.

Has Pharmaids Pharma declared dividend?

No Dividend History Available

Who are the peers of the Pharmaids Pharma?

Pharmaids Pharma's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Alpa Laboratorie, Panch. Organics, Syschem (India), Murae Organisor, and Bafna Pharma. Pharmaids Pharma has below average management risk and growth, with a 1-year return of 14.75%.

Peers: The peers of Pharmaids Pharma are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Alpa Laboratorie, Panch.Organics, Syschem (India), Murae Organisor, and Bafna Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at Alpa Laboratorie and Panch.Organics. Below Average management risk is present at Pharmaids Pharma, Syschem (India), Murae Organisor, and Bafna Pharma. Growth is Excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Murae Organisor, while Below Average growth is noted for Divi's Lab., Torrent Pharma, Pharmaids Pharma, Alpa Laboratorie, Panch.Organics, and the rest. Capital Structure is Excellent at Sun Pharma.Inds., Divi's Lab., Cipla, and Alpa Laboratorie, Good at Torrent Pharma and Bafna Pharma, while Below Average is seen at Pharmaids Pharma, Syschem (India), Murae Organisor, and the rest.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Panch.Organics has the lowest at -18.32%. Pharmaids Pharma's 1-year return is 14.75%, which is higher than Panch.Organics but lower than Divi's Lab. Additionally, the six-month return is negative for Panch.Organics, Pharmaids Pharma, and Murae Organisor.

Is Pharmaids Pharma overvalued or undervalued?

As of July 26, 2023, Pharmaids Pharma is considered a risky investment due to its negative PE ratio of -19.15, unfavorable valuation metrics compared to peers like Sun Pharma and Cipla, and a year-to-date stock performance of -17.99%, indicating it may be overvalued at its current price of 57.80.

As of 26 July 2023, Pharmaids Pharma's valuation grade has moved from does not qualify to risky, indicating a significant shift in its perceived investment quality. The company appears to be overvalued, especially when considering its negative PE ratio of -19.15, an EV to EBITDA of -18.92, and a ROE of -18.00%. These figures suggest that the company is struggling to generate profits relative to its valuation metrics.<BR><BR>In comparison to its peers, Pharmaids Pharma's valuation stands out unfavorably. For instance, Sun Pharma has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla, which is rated attractive, has a PE of 22.99 and an EV to EBITDA of 15.93. The stark contrast in these ratios highlights Pharmaids Pharma's challenges in the market. Additionally, the company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -17.99% compared to the Sensex's 5.62%, reinforcing the notion that it may be overvalued at its current price of 57.80.

What is the technical trend for Pharmaids Pharma?

As of June 2, 2025, Pharmaids Pharma's technical trend is mildly bearish, indicated by bearish MACD and KST signals on both weekly and monthly timeframes, despite some mixed signals from Bollinger Bands and mildly bullish daily moving averages.

As of 2 June 2025, the technical trend for Pharmaids Pharma has changed from sideways to mildly bearish. The weekly MACD and KST indicators are both mildly bearish, while the monthly MACD and KST also reflect a bearish stance. The RSI shows no signal on the weekly timeframe but is bearish on the monthly, indicating weakness. Bollinger Bands present a bearish signal on the weekly and mildly bullish on the monthly, suggesting mixed signals. Moving averages on the daily timeframe are mildly bullish, which contrasts with the overall bearish sentiment. Dow Theory confirms a mildly bearish stance on both weekly and monthly timeframes. Overall, the technical stance is mildly bearish, driven primarily by the MACD, KST, and Dow Theory indicators.

Who are the top shareholders of the Pharmaids Pharma?

The top shareholders of Pharmaids Pharma include promoter Sadhanala Venkata Rao with 4.4% and public shareholder Shankarappa Nagaraja Vinaya Babu with 19.91%. Individual investors collectively hold 36.59%, with no institutional holdings reported.

The top shareholders of Pharmaids Pharma include Sadhanala Venkata Rao, who is the promoter with the highest holding at 4.4%. Additionally, the highest public shareholder is Shankarappa Nagaraja Vinaya Babu, holding 19.91%. Individual investors collectively hold 36.59% of the shares. It's worth noting that there are no institutional holdings from mutual funds or foreign institutional investors.

When is the next results date for Pharmaids Pharma?

The next results date for Pharmaids Pharma is 11 November 2025.

The next results date for Pharmaids Pharma is scheduled for 11 November 2025.

Are Pharmaids Pharma latest results good or bad?

Pharmaids Pharmaceuticals' latest results show a mixed outlook, with a Q2 FY26 net loss of ₹2.48 crores, despite a 64.31% revenue growth to ₹8.61 crores. However, the company faces significant operational challenges, including a negative operating margin of -61.67% and rising costs, raising concerns about its long-term sustainability.

Pharmaids Pharmaceuticals' latest results present a mixed picture, but overall, they lean towards the negative side. In Q2 FY26, the company reported a consolidated net loss of ₹2.48 crores, which, while an improvement from the ₹4.91 crore loss in the previous quarter, still reflects a 28.50% deterioration year-on-year. <BR><BR>On the positive side, the company achieved a significant revenue growth of 64.31% year-on-year, reaching ₹8.61 crores. However, this growth has not translated into profitability, as evidenced by a deeply negative operating margin of -61.67%. The company's financial health is further challenged by rising employee costs and interest expenses, which have increased significantly, indicating a growing debt burden.<BR><BR>Overall, while revenue growth is a positive indicator, the persistent losses and negative operating margins signal serious operational challenges. The company is struggling to convert its sales into profits, raising concerns about its long-term sustainability. Investors should approach with caution given these ongoing issues.

How has been the historical performance of Pharmaids Pharma?

Pharmaids Pharma has seen net sales grow to 19.45 Cr in March 2025 from 0.00 Cr in March 2023, but continues to report significant losses, with an operating profit of -12.66 Cr and a profit after tax of -13.51 Cr in March 2025, alongside rising total assets and liabilities. Cash flow from operating activities remains negative at -13.00 Cr, indicating ongoing financial challenges.

Answer:<BR>The historical performance of Pharmaids Pharma shows a gradual increase in net sales, reaching 19.45 Cr in March 2025, up from 15.11 Cr in March 2024 and starting from 0.00 Cr in March 2023. However, the company has consistently reported negative operating profits, with an operating profit of -12.66 Cr in March 2025, slightly worse than -12.33 Cr in March 2024 and -9.88 Cr in March 2023. The total expenditure has risen to 32.21 Cr in March 2025 from 28.32 Cr in March 2024, contributing to a profit before tax of -17.28 Cr in March 2025, compared to -15.62 Cr in March 2024 and -9.91 Cr in March 2023. The profit after tax also reflects this trend, with losses of -13.51 Cr in March 2025, -11.84 Cr in March 2024, and -7.56 Cr in March 2023. The company's total assets increased to 109.35 Cr in March 2025 from 84.67 Cr in March 2024, while total liabilities also rose to 109.35 Cr from 84.67 Cr, indicating a growing financial burden. Cash flow from operating activities remained negative at -13.00 Cr in March 2025, worsening from -10.00 Cr in March 2024.<BR><BR>Breakdown:<BR>Pharmaids Pharma has demonstrated a notable increase in net sales over the past three years, achieving 19.45 Cr in March 2025, which marks a significant rise from 15.11 Cr in March 2024 and an initial 0.00 Cr in March 2023. Despite this growth in revenue, the company has faced persistent challenges with profitability, as evidenced by its operating profit margins remaining deeply negative, culminating in an operating profit of -12.66 Cr in March 2025. The total expenditure has also escalated, leading to a profit before tax of -17.28 Cr in March 2025, reflecting a deterioration in financial performance compared to previous years. The company's total assets and liabilities have both increased, reaching 109.35 Cr in March 2025, indicating a rise in financial obligations. Furthermore, the cash flow from operating activities has remained negative, highlighting ongoing operational difficulties. Overall, while Pharmaids Pharma has shown growth in sales, it continues to struggle with significant losses and rising costs.

Should I buy, sell or hold Pharmaids Pharma?

Why is Pharmaids Pharma falling/rising?

As of 02-Dec, Pharmaids Pharmaceuticals Ltd's stock price has risen to Rs 47.88, reflecting an 8.62% increase and outperforming its sector. This rise is supported by a 46.99% increase in investor participation and favorable trading conditions, despite a year-to-date decline of 32.07%.

As of 02-Dec, Pharmaids Pharmaceuticals Ltd is experiencing a rise in its stock price, currently at Rs 47.88, which reflects an increase of Rs 3.8 or 8.62%. This upward movement is notable as the stock has outperformed its sector by 8.61% today. The stock reached an intraday high of Rs 48, marking an increase of 8.89%. <BR><BR>Additionally, there has been a significant increase in investor participation, with delivery volume rising by 46.99% compared to the 5-day average, indicating heightened interest from investors. The stock's performance today contrasts with its recent trends, as it has underperformed against the benchmark Sensex over various periods, including a year-to-date decline of 32.07%. However, the current rise may be attributed to positive trading activity and increased liquidity, as the stock is liquid enough for trading sizes. <BR><BR>Overall, the combination of today's strong performance, increased investor participation, and favorable trading conditions contributes to the current rise in Pharmaids Pharmaceuticals Ltd's stock price.

Which are the latest news on Pharmaids Pharma?